Shopping Cart

Your shopping cart is currently empty

Seratrodast

Name: Seratrodast
Brand: TargetMol
SKU: T0212
Price: 34 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0212Cas No. 112665-43-7

Alias ABT-001, AA 2414

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

Seratrodast

Copy Product Info

😃Good

Purity: 99.69%

Catalog No. T0212Alias ABT-001, AA 2414Cas No. 112665-43-7

Pack Size	Price	USA Warehouse	Global Warehouse
10 mg	$34	In Stock	In Stock
25 mg	$61	In Stock	In Stock
50 mg	$85	In Stock	In Stock
100 mg	$123	In Stock	In Stock
500 mg	$297	-	In Stock
1 mL x 10 mM (in DMSO)	$37	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.69%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Seratrodast AI Summary

Seratrodast exhibits a broad range of bioactivities across multiple assays and targets. It shows potent inhibition of U-46619-induced contraction of guinea pig lung membranes (Kd = 5.129 nM) and U-44069-induced aggregation of guinea pig platelets (IC50 = 350.0 nM). Demonstrating significant efficacy in various biological systems, it effectively inhibits U-44,069-induced contraction of rabbit aorta and platelet aggregation, and possesses anti-bronchoconstriction properties validated by in vivo studies. Despite this, its inhibition effects on the vitamin D receptor, malarial parasite plastid, USP1/UAF1, and others, display significantly lower potency, most notably with USP1/UAF1 (89,125.1 nM) and vitamin D receptor (44,668.4 nM). Seratrodast shows moderate metabolic stability with high lipophilicity (LogD7.4 = 2.48), an intrinsic clearance of 85.0 uL.min-1.(10^6 cells)-1 in rat hepatocytes, and 3.0 mL.min-1.g-1 in human liver microsomes. It exhibits a high plasma protein binding of 98.0%. It also acts as an inhibitor of human BSEP (IC50 < 14,310.0 nM) and shows mixed results on cell viability across various cell types, such as HEK293T and U2OS cells. While exhibiting some antiviral activities against SARS-CoV-2 and Ebola Virus with low and mixed inhibitory effects, Seratrodast also demonstrates HDAC6 inhibition (36.44% inhibition in enzyme assay). Additionally, it affects the thermal stability of various protein domains and has significant, though variable, impacts on GPCR beta-arrestin recruitment assays across multiple targets. Overall, Seratrodast has significant potential in anti-inflammatory and anti-contraction applications with a diverse range of biological activities, though with relatively lower potency against several enzymes and receptors..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.
Synonyms	ABT-001, AA 2414

Chemical Properties

Molecular Weight	354.44
Formula	C₂₂H₂₆O₄
Cas No.	112665-43-7
Smiles	C(CCCCCC(O)=O)(C1=C(C)C(=O)C(C)=C(C)C1=O)C2=CC=CC=C2
Relative Density.	1.14 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (141.07 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 2.5 mg/mL (7.05 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.8214 mL	14.1068 mL	28.2135 mL	141.0676 mL
5 mM	0.5643 mL	2.8214 mL	5.6427 mL	28.2135 mL
10 mM	0.2821 mL	1.4107 mL	2.8214 mL	14.1068 mL
20 mM	0.1411 mL	0.7053 mL	1.4107 mL	7.0534 mL
50 mM	0.0564 mL	0.2821 mL	0.5643 mL	2.8214 mL
100 mM	0.0282 mL	0.1411 mL	0.2821 mL	1.4107 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc